ALVAC®-HIV (Vcp1521) Priming at Week 0, 4, 12, 24

Total Page:16

File Type:pdf, Size:1020Kb

ALVAC®-HIV (Vcp1521) Priming at Week 0, 4, 12, 24 Vaccine Trial Centre Established in1984 Funded by WHO on Control of Diarrhea Diseases Full operation in1986 Past 29 Years of Research Experiences • Cholera Vaccine Killed whole cell and B sub-unit oral vaccine CVD103-Hg resistant oral vaccine • Rotavirus Vaccine- Rotashield (tetravalent oral vaccine) • Poliomyelitis Vaccine (OPV & IPV) • Malaria Vaccine Varicella Vaccine • Measles Vaccine Cholera challenge-O1, O139 • WRSS1 Shigella Vaccine • HPV quadri-valent vaccine, nona- valent vaccine • H1N1 LAIV vaccine (WHO) H5N2 LAIV Vaccine (WHO) HIV Vaccine rgp 120 B, rgp 120 B/E ALVAC HIV Vaccine & rgp 120 B/E (Phase I/ II and III (RV144) RV305 RV306 Collaboration • AFRIMS – US, Thai • MHRP Military HIV Research Program • MOPH • Chulalongkorn University • Chiangmai University VTC Project Timeline 94 95 96 97 98 99 00 01 02 03 04 05 06 07 08 09 10 11 12 13 14 Projects Elderly flu vaccine RV306 GPO Avian Flu Vaccine-V02 RV305 Dengue CYD14 Dengue CYD34 V503-002 Nonavalent HPV vaccine in Preadolescents and Adolescents live attenuated influenza vaccine (PLAIV) V503-001 Nonavalent HPV vaccine Safety, Immunogenicity and Efficacy Studies of WRSS1 Measurement of Anogenital Wart Burden and Cost of Illnesses Herpes Zoster and Post-Herpetic Neuralgia Associated Establishment of a Shigella sonnei Challenge Model for Evaluation HIV-1 CM235 env/CM240 gag/pol vaccine HIV-1 gag DNA with or without IL-12 DNA Assessing the psychosocial burden in woman with abnormal pap Efficacy of GARDASIL™ in mid adults, HPV vaccine MRKAd5 HIV-1 vaccine ALVAC-HIV vaccine + gp 120 B/E vaccine boost Immunogenicity and Safety of Quadrivalent, HPV vaccine in young adults ALVAC-HIV vaccine + oligo gp 160 or gp 120 B/E vaccine boost ALVAC-HIV vaccine + gp 120 B/E vaccine boost Cholera Challenge in volunteers using frozen V.cholera 0139 bacteria AIDSVAX B/E gp 120 alum subtype B/E (AIDSVAX B/E) gp 120 MF 59 subtype B alone or with subtype E gp 120 alum subtype B Total-27 Phase I/II trials Phase III trials Surveillance Publications during 2004-2013 16 14 Total = 75 12 10 8 6 Number of publications of Number 4 2 0 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 year Most Cited Publications (Publications during 2004-2013) 79 Vaccine 2010; 28(4):950-7. 104 J Infect Dis 2004; 190:702-6. 137 Clin Infect Dis 2006; 42(12):1726-34. 143 J Antimicrob Chemother 2005; 56:745-755. 185 PLoS Med 2005; 2(10):390. 185 J Virol 2009; 83(14):7337-48. 266 Lancet 2009; 373(9679):1949-57. 294 N Engl J Med 2012;366(14):1275-86. 416 J Infect Dis 2006; 194(12):1661-1671. 663 Science 2009; 326(5950):285-9. 1274 N Engl J Med 2009; 361(23):2209-20. HIV-1 Vaccine Clinical Trials in Thailand 1) Injecting Drug users (IVDUs) A. 1995 Phase I/II AIDSVAXTM monovalent vaccine B. 1998 Phase I/II AIDSVAXTM B/E bivalent vaccine C. 1999 -2003 Phase III AIDSVAXTM B/E vaccine 2) Healthy, Community participation A. 1998 Phase I/II Chiron gp120/MF59 subtype E antigen alone or combined with B antigen B. 2000 Phase I/II ALVAC vaccine(vCP1521) prime AIDSVAXTM vaccine boost C. 2003- 2009 Phase III of AlVAC priming and AIDSVAX boosting (RV144) D. 2003- 2009 Phase I MRK HIV-I Vaccine E. 2012-2014 RV305 F. 2013- RV306 AIDSVACCINE Trial IN THAILAND 94 95 96 97 98 99 00 01 02 03 04 05 06 07 08 09 10 11 12 13 RV306 RV305 HIV-1 CM235 env/CM240 gag/pol vaccine HIV-1 gag DNA with or without IL-12 DNA pHIS-HIV-AE (DNA) and rFPY-HIV-AE MRKAd5 HIV-1 vaccine ALVAC-HIV vaccine + gp 120 B/E vaccine boost ALVAC-HIV vaccine + oligo gp 160 or gp 120 B/E vaccine boost ALVAC-HIV vaccine + gp 120 B/E vaccine boost AIDSVAX B/E gp 120 alum subtype B/E (AIDSVAX B/E) gp 120 MF 59 subtype B alone or with subtype E gp 120 alum subtype B gp 120 MF 59subtype B Peptide V3-MAPS PREVENT ESTABLISHED INFECTION? ***** Immune responses against HIV Jhonston M and Fauci A. NEJM,2007,May17;356(20):2073-81 Scientific and Non-scientific Obstacles to the Development of an HIV Vaccine • Clearance of HIV in an HIV-infected individual has not been demonstrated, suggesting that the innate and adaptive immune defense system cannot overcome the virus. • Extensive viral subtype and sequence diversity limits the efficacy of current vaccine approaches to specific subtypes. • Rapid changes in HIV genetic sequences as well as phenotypic features allow HIV to escape from immune suppression. Source: Adapted from Barouch (2008) • Super infection suggests that immune responses induced by one virus have no protective activity against the subsequent infection. • There is a narrow window of opportunity for the immune system to clear initial infection before establishment of latent viral reservoirs. • Immune correlates of protection remain poorly understood. • Viral escape from humeral and cellular immune responses may limit sustained efficacy. Source: Adapted from Barouch (2008) Obstacles to the Development of an HIV Vaccine • Conserved antibody targets on the outer envelope protein are hidden. • Appropriate animal models that can truly predict efficacy in humans are lacking. • The interest of the pharmaceutical industry is limited. • Long-term sustained commitment from governments and donors is limited. Source: Adapted from Barouch (2008) Recombinant protein (gp120) AIDSVAX B/B’ or B/E DNA Live-recombinant vectors • Using Ad5 Virus –MRKAd5 • Or ALVAC virus (bird pox virus) ALVAC HIV vaccine Efficacy studies thus far Study Year Population Vaccine Vaccine Efficacy IDUs(Thailand) VAX Vax003-0.1% 1997-02 MSM(North AIDSVAX 003,004 (95% CI:30.8%-23.8%) America) 24/741 V became HIV-1 infected VS Seronegative high STEP 2005-07 MRKAd5 21/762 P risk voulnteers, Hazard ratio 1.2 US (95% CI 0.6-2.2) ALVAC, 31.2% RV144 2003-09 Community risk (95% CI: 1.1-51.2 AIDSVAX Thailand p-value: 0.04) HIV-negative men 41 HIV infection in volunteers HVTN and transgender DNA, 2009-13 receiving vaccine and 30 cases 505 women who have MRKAD5 in those receiving placebo. Pitisuttithum, et al. JID 2006 sex with men, US M Robertson, et al. Available at http://www.hvtn.org/science/step_buch.html Supachai Rerks-Ngarm, et al. N Engl J Med 2009 HVTN505: SOURCE: http://www.aidsmap.com/Researchers-stop-the-only-current-HIV-vaccine-efficacy-trial/page/2640732/ RV144: Prime - Boost strategy using two different vaccines:for inducing both humeral and cell mediated immunity Prime Vaccine: ALVAC-HIV (vCP1521) from Sanofi Pasteur • Recombinant canarypox virus expressing the product of HIV-1 env, gag and protease genes gp120 env from Thai subtype E (92TH023) gp41, gag, and protease from LAI (subtype B) Booster vaccine: AIDSVAX ® B/E from VaxGen Inc. • Recombinant gp120 from MN(subtype B)and A244 (subtype E) • 16,402 HIV-negative men and women were enrolled. • 13,978 participants had completed full series of vaccinations HIV test, risk assessment and counseling 0.5 1 2 3 (time in years) 6-month vaccination schedule 3 years of follow-up (every 6 mo.) ALVAC®-HIV (vCP1521) priming at week 0, 4, 12, 24 AIDSVAX® B/E gp120 boosting at week 12, 24 Challenges in site preparation • Require massive infrastructure strengthening, capacity building (8 clinical sites at the district level) • Personnel and staffing : training of various level of staffs on GCP, Protocol, SOP etc. (120 full time and 200 part time ) • Establishing Trial Registry and Repository Center at MOPH (>100,000 specimens were collected) • HIV ELISA with electronic reporting system with VALIDITY system at AFRIMS • Vaccine depository center (approx.109,000 vaccine vials delivered and kept in batches) • Data management with Data fax,validating system at Mahidol U.( millions pages of case report forms) Role of VTC staffs & CRC(s) • Enrollment • Vaccination • Reactogenicity, AE(s), SAE(s), documentation, reporting and follow up Clinical Team VTC MD Director-MOPH • SI • MD Supervisor - 5 • Nurse (6 - 10/site) • VTC CRC - 5 • CRC - CRC 5/site - Pharmacist 2/site Total 150 full time - RA 2/site staff and 200 part times Clinic Activities Inform consent process • Video presentation, • Group discussion • Individual discussion • Mini –exam T/F and need to get 80% marks before signing consent form RA Registry VDO informed consent Group informed consent Individual Informed Consent Vital Signs Urine Pregnancy Test (Only Female) Medical History and Blood Draw Eligibility Check VACCINE STORAGE VACCINE CODE PHARMACIST DOCUMENTATION &preparation Training CRC, RA, Pharmacist Screening all sites (N = 26,658) Male 15,973 (60%) Female 10,685 (40%) Enrollment all sites (N = 16,402) Male 10,068 (61%) Female 6,334 (39%) Participants with age under 20 yrs (N =2,540) Male 1,658 (65%) Female 882 (35%) 13,977 volunteers received all 4 vaccinations 90% follow up at three years Retention and clinical activities at the sites ( started from 2005) Extend Service Hours on Sunday 24-hour Mailing Edutainment and one evening phone and campaigns/ Provider clinic per week access phone interactive based games system reminders 16,402 90% volunteers interval Enrolled Retention Mobile Tracking Volunteer Cultural Quarterly unit activities Relation, activities exhibition activities (Home Club visit) activities with educational boards Provider based system: • The volunteers are entitled for receiving care and follow up continuously by the same staff. • This was aimed to establish closed relation between the volunteers and clinical staff and to increase volunteers’ satisfaction of services. • Volunteer satisfaction survey was conducted in 1,523 volunteers at clinical sites ( from 13/09/06 to 27/09/06). 1,141 volunteers (93%) expressed their satisfaction in provider based system.
Recommended publications
  • A Media Handbook for HIV Vaccine Trials for Africa Acknowledgements
    A Media Handbook for HIV Vaccine Trials for Africa Acknowledgements The Media Handbook for HIV Vaccine Trials for Africa was written by Yinka Adeyemi with guidance and direction from Bunmi Makinwa of the department of Policy, Strategy and Research, Dr Jose Esparza, Dr Saladin Osmanov, Claire Pattou, and Coumba Touré of the World Health Organization (WHO)/Joint United Nations Programme on HIV/AIDS (UNAIDS), HIV Vaccine Initiative. We would like to acknowledge the following individuals for their valuable comments and contributions to this handbook: Dr Alashle Abimiku, Dr Omu Anzala, Dr Carlos Arnaldo, Dr Courtney Batholomew, Janet Frohlich, Dr D. A. Gangakhedar, Dr Rodney Hoff. Patrick Jabani, Bachi Karkaria, Dr Tom LaSalvia, Dr Chewe Luo, Nebat Mbewe, Dr Rosemary Musonda, Binod Mahanty, Dr Roy Mugerwa, Ronaldo Mussauer de Lima, Omololu Falobi, Otula Owuor, Kirk Pereira, Dr John Rwomushana, Mario Scheffer, Jaya Shreedhar, Judith Soal, Dr Prasert Thongcharoen, Kathy Ann Waterman and Victor Zonana. The section on Communication and vaccine trials in Thailand (Appendix 1) is based on a UNAIDS report by Nusara Thaitawat, while that on Communication issues in vaccine trials in Uganda (Appendix 2) is based on a UNAIDS report by Ann Fieldler. The section on Communication and preparations for HIV vaccine trials in Kenya (Appendix 3) is by Otula Owuor. A number of fictitious people and organizations are used for illustrative purposes within the text. Any reference to actual persons or organizations is purely coincidental. UNAIDS/01.05E (English original, February 2001) ISBN 92-9173-021-1 © Joint United Nations Programme on HIV/AIDS The designations employed and the presentation of the (UNAIDS) 2001.
    [Show full text]
  • Phase III HIV Vaccine Trial—Thailand
    HIV Vaccine Efficacy Trials; Lessons and Opportunities for Future Research Hannah Kibuuka Makerere University Walter Reed Project, Uganda INTEREST Conference Harare, Zimbabwe Outline . Need for an HIV Vaccine . Efficacy Trials up to date . Lessons from failed Efficacy trials and opportunities for Research . Lessons form RV 144 and P5 follow up studies Before After vaccines vaccines Vaccines work really well! Vaccines are among the most successful medical interventions (eradicated or controlled smallpox, polio, measles…) A Vaccine Is Essential to End AIDS Potential impact of an AIDS vaccine as part of the UNAIDS Enhanced Investment Framework (IFE) Cumulative infections 2.000.000 avoided 2027-70 Current Trend 42.7M Current Trend + Vaccine* 1.500.000 50% Scale-up 27.1M 1.000.000 50% Scale-up + Vaccine* New Infections with HIV HIV with Infections New 500.000 IFE 16.2M IFE + Vaccine* 0 2010 2015 2020 2025 2030 2035 2040 2045 2050 2055 2060 2065 2070 * Illustrative vaccine with an assumed efficacy of 70%, not representative of any specific candidate. Coverage in generalized epidemics: routine 10 years old 70%, catch-up 11-14 years old 60%, 15-17 years old 55%, 18-49 years old 50%; in high risk populations in concentrated epidemics: 50% Modeling project – UNAIDS, Futures Institute, IAVI, AVAC [funded by USAID] 3 Need….. Several new prevention measures have been realized in the last few years. Although efficacious, the interventions are faced with potential challenges of access and adherence . HIV vaccine has potential to address some of these
    [Show full text]
  • HPV Vaccination to Prevent HIV Infection: Time for Randomized Controlled Trials Maarten F
    COMMENTARY HPV Vaccination to Prevent HIV Infection: Time for Randomized Controlled Trials Maarten F. Schim van der Loeff, MD, PhD,*† Alan G. Nyitray, PhD,‡ and Anna R. Giuliano, PhD‡ Despite many years of rigorous evaluation of a variety of interventions, HIV incidence rates in parts of Africa remain unacceptably high. A recent review identified 37 randomized controlled trials testing interventions to reduce HIV incidence.1 Except for 3 randomized controlled trials of male circumcision2–4 and 1 trial of syndromic treatment of sexually transmitted diseases,5 and, recently, 1 trial of a vaginal microbicide,6 no significant reductions in HIV incidence were observed. In some trials of vaginal microbicides, trial participants in the active treatment arm actually had increased HIV incidence rates.7 Trials with candidate vaccines have been equally disappointing.8 A recently completed trial of a prime-boost strategy conducted in Thailand showed statistically significant, but limited, protection against HIV.9 Nevertheless, even vaccine optimists think that a preventive HIV vaccine is many years away. Sexually transmitted infections (STIs) were identified as important cofactors for HIV trans- mission early in the epidemic.10,11 Many prospective observational studies showed that the presence of ulcerative and nonulcerative STIs increased the likelihood of HIV transmission.10,11 Several interventions were based on this observation including mass treatment with antibiotics,12 improved syndromic management of STIs,5,13 and herpes simplex virus (HSV)-2 suppressive treatment.14 Null findings of these interventions should be interpreted with caution. Failure to show an effect does not necessarily mean that the STI is not causally associated with HIV.
    [Show full text]
  • Impact of Vaccine Type on HIV-1 Vaccine Elicited Antibody Durability
    www.nature.com/scientificreports OPEN Impact of vaccine type on HIV‑1 vaccine elicited antibody durability and B cell gene signature Rohith Palli1,2,15, Kelly E. Seaton3,15, Michael S. Piepenbrink4, John Hural5, Paul A. Goepfert4, Fatima Laher6, Susan P. Buchbinder7, Gavin Churchyard8, Glenda E. Gray6,9, Harriet L. Robinson10, Yunda Huang5, Holly Janes5,11, James J. Kobie4, Michael C. Keefer12, Georgia D. Tomaras3 & Juilee Thakar13,14* Efcacious HIV‑1 vaccination requires elicitation of long‑lived antibody responses. However, our understanding of how diferent vaccine types elicit durable antibody responses is lacking. To assess the impact of vaccine type on antibody responses, we measured IgG isotypes against four consensus HIV antigens from 2 weeks to 10 years post HIV‑1 vaccination and used mixed efects models to estimate half‑life of responses in four human clinical trials. Compared to protein‑boosted regimens, half‑lives of gp120‑specifc antibodies were longer but peak magnitudes were lower in Modifed Vaccinia Ankara (MVA)‑boosted regimens. Furthermore, gp120‑specifc B cell transcriptomics from MVA‑boosted and protein‑boosted vaccines revealed a distinct signature at a peak (2 weeks after last vaccination) including CD19, CD40, and FCRL2‑5 activation along with increased B cell receptor signaling. Additional analysis revealed contributions of RIG‑I‑like receptor pathway and genes such as SMAD5 and IL‑32 to antibody durability. Thus, this study provides novel insights into vaccine induced antibody durability and B‑cell receptor signaling. While vaccine-elicited antibody durability has been achieved for licensed vaccines such as yellow fever, measles, smallpox, and Hepatitis B, elicitation of long-lived, functional antibody responses with candidate HIV-1 vac- cine regimens remains elusive1,2.
    [Show full text]
  • Lessons Drawn from Recent HIV Vaccine Efficacy Trials
    SUPPLEMENT ARTICLE Lessons Drawn From Recent HIV Vaccine Efficacy Trials Jonathan D. Fuchs, MD, MPH,*† Magda E. Sobieszczyk, MD, MPH,§ Scott M. Hammer, MD,§ and Susan P. Buchbinder, MD*†‡ has not delivered one. A recently completed vaccine efficacy Abstract: A safe and effective HIV vaccine is needed to curtail the trial has inspired new hope that an HIV vaccine is US and global epidemics. However, the search for one has been achievable. Here we describe how the results from these elusive despite more than 25 years of focused research. Results from large clinical studies, some unexpected, are driving vaccine the RV144 Thai efficacy trial have renewed hope that a vaccine may discovery. We also outline important lessons about data protect against HIV acquisition. We can draw several scientific and analysis, dissemination, and recruitment of communities operational lessons from RV144 and other recent tests-of-concept at risk. efficacy trials. Here we describe how trial results, some unexpected, highlight the fundamental role these clinical studies play in HIV vaccine discovery. These trials also teach us that transparency in data HIV VACCINE EFFICACY TRIALS TO DATE analysis and results dissemination can yield substantial rewards and Since the first gp160 vaccine entered clinical testing in that efforts to engage communities, particularly those most heavily 1987, more than 150 trials of different vaccine candidates have affected by the epidemic, are needed to augment research literacy and been conducted.2 These trials reflect 3 distinct waves of trial recruitment. Future efficacy trial designs may incorporate novel, vaccine development, including approaches designed to elicit partially effective prevention strategies.
    [Show full text]
  • Revised Vaccine Fact Sheet.Qxd
    can an HIV vaccine make a difference? why do we need an HIV vaccine? revised 1/04 accines are among the most powerful and cost-effective disease prevention tools Vavailable. A vaccine that could prevent HIV infection or stop progression of the disease would greatly help in the fight against the AIDS pandemic. Vaccines have been pivotal in worldwide smallpox elimination efforts, have nearly eliminated polio and have drastically ays who? reduced the incidence of infectious diseases like measles and pertussis in the US. S A crucial question is whether a vaccine based on one strain of HIV would be effective for 1. National Institute of Allergy and populations in which a different strain is predominant. There are also questions about how Infectious Diseases. Challenges an HIV vaccine would protect individuals: the vaccine might not be able to actually in designing AIDS vaccines. May prevent infection, but could prevent or delay progression to disease, or simply reduce the 2003. www.niaid.nih.gov/ infectiousness of people who do become infected with HIV. factsheets/challvacc.htm HIV prevention education and counseling are important components of vaccine programs. Even after the release of a vaccine, there will be an ongoing need for effective behavioral 2. AIDS Vaccine Advocacy prevention programs. An HIV vaccine will not be a “magic bullet” but it could play an Coalition. Understanding the extremely powerful role as part of a package of prevention interventions. results of the AIDSVAX trial. May 2003. www.avac.org/pdf/ UnderstandingAIDSVAX.pdf has progress been made? 3. VaxGen Announces Results of its Phase III HIV Vaccine Trial in wenty-two years into the epidemic, researchers are still struggling with the daunting Thailand: Vaccine Fails to Meet Tscientific challenges involved in HIV vaccine research: 1) traditional approaches to Endpoints.
    [Show full text]
  • HIV Vaccines in Canada
    The Global Effort Some progress has been made in the global effort to find an HIV vaccine. Advances in molecular biolo- gy and basic HIV research have led to the develop- ment of promising strategies. Some experimental 1 vaccines have shown the ability to protect non- human primates from infection by a virus closely related to HIV. A number of candidate vaccines HIV have been shown to be safe in small-scale (Phase I Vaccines and II) clinical trials and to trigger HIV-specific in Canada immune responses. Some people repeatedly exposed to HIV resist infection and mount HIV specific immune responses, which provides important clues for the design of an effective HIV vaccine. There is a growing scientific consensus that an effective HIV vaccine is possible. Since 1987, when the first HIV vaccine trial was conducted, about 30 candidate vaccines have been tested in approximately 60 phase I/II clinical trials, Current State involving more than 10,000 healthy human volun- teers. Two candidate vaccines are undergoing large-scale (Phase III) efficacy evaluation in North of HIV Vaccine America, the Netherlands, and Thailand. The final results from these trials are expected in 2003. A Phase III trial of another candidate vaccine is Research scheduled to start in early 2003 in Thailand, with results expected by 2007. This info sheet reviews the state of HIV vaccine research No precise figures are available on the amount globally and in Canada as of March 2002. of money being spent on HIV vaccine research globally, but estimates range from $US 450 to 600 million a year.
    [Show full text]
  • Health Advances' Insights
    Health Advances’ Insights: SI Technology (formerly called “Core Shell”) • Single Injection (SI) technology has multiple applications and potential for huge impact • Prioritization according to technical fit and unmet clinical need is essential to de-risked development – 50 vaccines were screened • Rabies is the best first application and model drug for building out the technology platform • Strong technical fit and unmet need in low-and-middle-income-countries (LMICs) • Convert the lab scale process into commercially viable process with rabies before moving to more technically challenging, larger impact applications • WHO Pre-Qualification helps make vaccines accessible in LMICs • Requires regulatory approval in US, Europe, India or other WHO designated countries 1 Table of Contents Content Slide # Source Disclaimer 3 Particles for Humanity Executive Summary 4-13 Health Advances Priority Applications 14-39 Health Advances • Rabies • Meningococcus • HPV • HIV/AIDS Other Applications 40-63 Health Advances • Polio • Malaria • Hepatitis A • Group B Strep Regulatory Process 64-72 Health Advances Appendix: Vaccine Market Segmentation 73-74 Health Advances 2 Disclaimer • The following deck was an independent analysis conducted by Health Advances on the potential applications of the single injection (SI) technology in 2018 and may not represent the current views of Particles for Humanity • Refer to the SI Development Plan for details regarding our team and timeline • Health Advances work 1. Examines burden of disease/ potential for impact, clinical need, value propositions, and technical fit with the technology for 50 vaccines that were screened 2. Lays out the development and regulatory pathway for applications 3 Health Advances LLC Presented to BOSTON | SAN FRANCISCO | ZUG www.healthadvances.com Particles for Humanity November 20, 2018 Background & Objectives Executive Summary • The Gates Foundation is interested in funding innovative vaccine technology platforms for the developing world.
    [Show full text]
  • Company Description Key Points Geovax Labs, Inc. GOVX-NASDAQ
    GeoVax Labs, Inc. GOVX‐NASDAQ EXECUTIVE INFORMATIONAL OVERVIEW® October 22, 2020 Company Description GeoVax Labs, Inc. (“GeoVax” or “the Company”) is a clinical‐stage biotechnology company developing preventive and therapeutic human vaccines against infectious diseases and cancer. The GeoVax Labs, Inc. Company’s proprietary GV‐MVA‐VLP™ vector vaccine technology 1900 Lake Park Drive, Suite 380 utilizes a Modified Vaccinia Ankara (MVA) vector, a large virus Atlanta, GA 30080 capable of carrying several vaccine antigens, that are expressed as Phone (678) 384‐7220 non‐infectious virus‐like particles (VLPs) in the individual receiving Fax (678) 384‐7281 the vaccine (in vivo). VLPs mimic a natural infection, stimulating both www.geovax.com the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection through durable immune Ticker (Exchange) GOVX (NASDAQ) responses. GeoVax is capitalizing on the safety and efficacy of its Recent Price (10/22/2020) $3.19 technology platform to address the urgent need for a COVID‐19 Shares Outstanding* 3.8 million vaccine and is also developing vaccines against human immunodeficiency virus (HIV), Zika virus (ZIKV), hemorrhagic fever Market Capitalization $11.4 million (HF) viruses (Ebola, Sudan, Marburg, and Lassa Fever) and malaria. Average 3‐month Volume 377,347 Furthermore, the Company is applying its MVA‐VLP technology to Insider Ownership +>5% 6.9% cancer immunotherapy (immuno‐oncology). Institutional Ownership 25% EPS (06/30/2020)* ($0.66) Key Points Employees 8 GeoVax’s recently completed $12.8 million public offering and its * EPS figure for Q2 2020 has been restated for the 1:20 reverse uplist to Nasdaq give it the financial resources it has lacked in recent split in September 2020.
    [Show full text]
  • Report to SAGE on Achievement of Previous Recommendations & Progress Highlights
    Report to SAGE on achievement of previous recommendations & Progress highlights SAGE Meeting, 27-29 October 2009 J.M. Okwo-Bele, WHO Outline Follow-up of previous meetings and recommendations Pneumococcal conjugate vaccines Japanese Encephalitis HPV vaccine Rotavirus vaccines Hepatitis B Lower middle-income countries (LMICs) financing Update on latest global developments Briefs on WHO/IVB Department activities State of the worlds vaccines and immunization 3rd Edition (SOWVI) Strategic plan 2010-15 Addressing Stakeholders' panel recommendations Technologies & Logistics Advisory Committee Topics on the horizon for SAGE meetings 2 | SAGE meeting, 27-29 October 2009 Pneumococcal Conjugate Vaccine, 2009 29 countries have introduced PCV7, including Rwanda in Apr 09 and the Gambia through Wyeth donation and GAVI support 14 countries (11 GAVI eligible) interested to introduce PCV10 or PCV13 9 new applications to GAVI in Oct 2009 * Honduras, Panama and Saudi Arabia **For Barbados, Costa Rica, have the vaccine in their schedule in Mexico, Micronesia, New Zealand 2008 for risk groups only and Sweden and Palau: data not confirmed. has it in parts of the country No (78 countries or 40%) Introduction in 2009 or GAVI Approved* (14 countries or 7%) Yes** (26 countries or 13%) Applied for GAVI Support – Not yet Approved (3 countries or 2%) Yes part of the country (3 countries or 2%) Never Applied for GAVI Support (58 countries or 31%) Yes risk groups (11 countries or 6%) The boundaries and names shown and the designations used on this map do Source: WHO/IVB database, 193 WHO Member States. Data not imply the expression of any opinion whatsoever on the part of the as of June 2009 World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of 3 | SAGE meeting, 27-29 October 2009 its frontiers or boundaries.
    [Show full text]
  • Simplified Steps to Heterologous Prime-Boost HIV Vaccine Development?
    Simplified steps to heterologous prime-boost HIV vaccine development? Nelson L. Michael J Clin Invest. 2019;129(11):4572-4573. https://doi.org/10.1172/JCI132440. Commentary The RV 144 HIV vaccine efficacy study showed a reduction in HIV-1 infection risk in Thai volunteers who received two priming vaccinations of vCP1521 ALVAC (attenuated recombinant canarypox virus expressing HIV group–specific antigen, polymerase, and envelope genes) followed by two additional ALVAC vaccinations and coadministration of purified bivalent gp120 proteins (AIDSVAX B/E). In this issue of the JCI, Rouphael et al. build on these results by substituting a DNA plasmid cocktail expressing HIV-1 subtype C group–specific antigen, polymerase, and envelope antigen genes (DNA-HIV-PT123) for ALVAC in a phase 1b safety and immunogenicity study. The results indicate that the vaccine regimen is safe, elicits promising cross-subtype humoral and cellular responses, and opens up potentially simplified approaches to HIV-1 vaccine development. Find the latest version: https://jci.me/132440/pdf COMMENTARY The Journal of Clinical Investigation Simplified steps to heterologous prime-boost HIV vaccine development? Nelson L. Michael Center for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA. replaced in the current study by a cocktail of three DNA plasmids, DNA-HIV-PT123, The RV 144 HIV vaccine efficacy study showed a reduction in HIV-1 which consists of equal amounts of plas- infection risk in Thai volunteers who received two priming vaccinations of mids expressing HIV-1 subtype C sequenc- vCP1521 ALVAC (attenuated recombinant canarypox virus expressing HIV es: HIV-1 gag, HIV-1 gp140, and group–specific antigen, polymerase, and envelope genes) followed by two ZM96 ZM96 HIV-1CN54 pol-nef, delivered at a total dose additional ALVAC vaccinations and coadministration of purified bivalent of 4 mg administered intramuscularly via gp120 proteins (AIDSVAX B/E).
    [Show full text]
  • Understanding the Results of the AIDSVAX Trial
    A Special Update Understanding the Results of the AIDSVAX Trial This version, dated May 14, 2003, will be updated as more information becomes available. AVAC | AIDS VACCINE ADVOCACY COALITION — MAY 14, 2003 AIDS Vaccine Advocacy Coalition ■ page 1 Understanding the Results of the AIDSVAX Trial n late February 2003, the world heard prelimi- nary results of the first large scale human trial of a vaccine designed to prevent HIV infection.The What do we know from results for the overall trial cohort were clear and disappointing. The results for a relatively small the AIDSVAX trial? Isubset of trial participants are less clear, and they • The vaccine did not protect against HIV have sparked controversy and require further analy- infection in the overall study group. sis.This brochure will help you understand what we do and do not know about the experimental vaccine • The company that makes AIDSVAX known as AIDSVAX. AVAC will update this document presented interesting data on subgroups as more data becomes available. and this data should be thoroughly and openly analyzed. If warranted, further study should be done. What’s the bottom line? AIDSVAX did not prevent HIV infection in the study •Itis too early to draw any conclusions population (see “Who Were the Trial Volunteers?”). about the effects of AIDSVAX in any But VaxGen, the vaccine’s maker, presented its subgroup. analysis of subgroup data that the company said showed “a statistically significant reduction of HIV •AIDS vaccine e≤cacy trials are possible. infection in certain vaccinated groups,” including The AIDSVAX North American trial lower infection rates in “ethnic minorities, other demonstrated that it is possible to recruit than Hispanic individuals”.
    [Show full text]